Back

Should all diabetic patients be treated with GLP-1 agonists?

28 August 2021 (12:15 - 12:30)
Organised by:
Congress Presentation Part of: Meet the Experts: new cardiorenal pharmacotherapy for diabetes Pharmacology and Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Associate Professor Linda Mellbin

Karolinska University Hospital, Stockholm (Sweden)

2 More presentations in this session

Presentation thumbnail
Should all diabetic patients be treated with SGLT2 inhibitors?
Professor F. Cosentino (Stockholm, SE)
Slides Video
Presentation thumbnail
Meet the Experts: new cardiorenal pharmacotherapy for diabetes – discussion.

Access the full session

Session thumbnail
Meet the Experts: new cardiorenal pharmacotherapy for diabetes
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

28 August 2021 12:15 CET
You may be interested in
thumbnail
Congress Presentation
All diabetic patients should be treated with GLP1 and/or GIP agonists.
29 August 2022
thumbnail
Congress Presentation
Percentage and main features of patients referred to a cardiac rehabilitation program who would have an indication for a GLP1 receptor agonist based on the SELECT trial criteria
25 April 2024
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025
thumbnail
Congress Presentation
The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources